๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma

โœ Scribed by Elizabeth A. Eisenhauer; William K. Evans; Nevin Murray; Walter Kocha; Rafal Wierzbicki; Kenneth Wilson

Publisher
Springer US
Year
1988
Tongue
English
Weight
204 KB
Volume
6
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of VP-16 100 mg/m 2 daily x 3 and cisplatin 25 mg/m 2 daily x 3 in untreated patients with malignant mesothelioma. Twenty-seven eligible patients were entered on the trial and the majority had pleural and/or soft tissue disease. Myelosuppression and gastrointestinal symptoms were the most common toxicities, and were usually mild or moderate in severity. Only 3 partial responses were seen in the 26 patients evaluable (12%). We conclude that the combination of VP-16 and cisplatin when used in this fashion has only minimal activity in mesothelioma.

๐Ÿ“œ SIMILAR VOLUMES

A phase II evaluation of cisplatin in un
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
โœ Bernard L. Zidar; Stephanie Green; H. I. Pierce; Ralph W. Roach; Stanley P. Balc ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 240 KB

Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disea

A phase II study of gemcitabine in patie
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
โœ Jan P. van Meerbeeck; Paul Baas; Channa Debruyne; Harry J. Groen; Chris Manegold ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB ๐Ÿ‘ 2 views

## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo

Gemcitabine combined with carboplatin in
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma : A multicentric Phase II study
โœ Adolfo G. Favaretto; Savina M. L. Aversa; Adriano Paccagnella; Vincenzo De Pangh ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide. Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated.